MRK vs BMY
Merck · Bristol-Myers Squibb
| MRK Merck Healthcare | BMY Bristol-Myers Squibb Healthcare | |
|---|---|---|
| Market | ||
| Price | $149.52 +2.18% | $62.48 +1.78% |
| Market cap | $368.9B | $127.6B |
| P/E (TTM) | 116.3 | 13.8 |
| Dividend yield | 2.87% | 4.58% |
| 52-week range | $82.01 – $156.92 | $43.20 – $68.64 |
| Our research | ||
| Our view | LONG open | LONG open |
| Articles | 1 | 1 |
| Latest article | Merck (MRK): Revenue Up 5%, But $550M Of Purchase Timing Was About Two-Thirds Of The Incr… Nov 1, 2026 | Bristol-Myers Squibb: The Forensic Case That The Patent Cliff Math Has Already Been Solved May 27, 2026 |
| Latest earnings | ||
| Reported | Oct 29, 2026 | Oct 29, 2026 |
| Revenue | — | $13.1 billion +7% YoY |
| EPS | $2.04 | $1.05 |
| Guidance | Guidance issued | Guidance raised |
| Revenue growth, last 4 reports | — | +7% |
| Topics | ||
| Main topics | ||
| Company page · Earnings releases | Company page · Earnings releases | |
Note. Earnings figures are extracted automatically from each company's own release; prices are delayed up to 15 minutes. This comparison is information, not investment advice.